Signature Equity Partners’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Signature Equity Partners’s Portfolio QNTM Stock Details QNTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20	Closed	-$146	–	1673
2025 Q4	$146	Buy	+20	New	+$218	﹤0.01%	1659

Other funds holding QNTM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Signature Equity Partners's QNTM Position: Q1 2026 in Review

Signature Equity Partners sold out of Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q1 2026, closing a stake of 20 shares — an estimated $146 sold.

Signature Equity Partners first reported a position in QNTM in Q4 2025 and held it in 1 quarter. The position peaked at $146 in Q4 2025. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

Signature Equity Partners reported no remaining Quantum Biopharma Class B Subordinate Voting Shares position as of Q1 2026 after selling out during the quarter.
Signature Equity Partners sold 20 Quantum Biopharma Class B Subordinate Voting Shares shares in Q1 2026, an estimated $146.
Signature Equity Partners first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q4 2025 and held it in 1 quarter.
Signature Equity Partners's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $146 in Q4 2025.
25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.